Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...